Topic
Angiogenesis
About: Angiogenesis is a research topic. Over the lifetime, 58248 publications have been published within this topic receiving 3290129 citations. The topic is also known as: blood vessel formation from pre-existing blood vessels & GO:0001525.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This review focuses on the ambivalent role of EMP in vascular homeostasis and investigates whether EMP could promote cell survival, exert antiinflammatory effects, counteract coagulation processes, or induce endothelial regeneration.
Abstract: Endothelial microparticles (EMP) are complex vesicular structures shed from activated or apoptotic endothelial cells. They play a remarkable role in coagulation, inflammation, endothelial function, and angiogenesis and thus disturb the vascular homeostasis, contributing to the progression of vascular diseases. As a cause or a consequence, elevated levels of EMP were found in plasma from patients with vascular diseases, where they serve as a surrogate marker of endothelial function. More recent data challenged the presumed deleterious role of EMP because they could promote cell survival, exert antiinflammatory effects, counteract coagulation processes, or induce endothelial regeneration. This review focuses on the ambivalent role of EMP in vascular homeostasis.
573 citations
•
TL;DR: The collective data suggest that the profound in vivo antitumor activity identified in the xenograft setting when C225 is combined with radiation derives from more than simply the antiproliferative and cell cycle effects of EGFR system inhibition.
Abstract: We
have recently demonstrated that molecular blockade of the epidermal
growth factor receptor with the anti-epidermal growth factor receptor
(EGFR) monoclonal antibody C225 enhances the in vitro
radiosensitivity of human squamous cell carcinomas (SCCs) derived from
the head and neck. In the present study, we further investigated the
capacity of C225 to modulate the in vitro and in
vivo radiation response of human SCC tumor cells and
xenografts, and we examined several potential mechanisms that may
contribute to the enhanced radiation response induced by C225. Tumor
xenograft studies demonstrated complete regression of both newly
established (20 mm 3 ) and well-established (100
mm 3 ) SCC tumors over a 55–100 day follow-up period in
athymic mice treated with the combination of C225 (i.p. injection) and
radiation. Cell cycle analysis via flow cytometry confirmed that
combined treatment with C225 and radiation induced an accumulation of
cells in the more radiosensitive cell cycle phases (G 1 ,
G 2 -M) with concurrent reduction in the proportion of cells
in the more radioresistant S phase. Results from sublethal damage
repair and potentially lethal damage repair analyses in cultured SCC
cells demonstrated a strong inhibitory effect of C225 on postradiation
damage repair. Further, exposure of SCC cells to C225 induced a
redistribution of DNA-dependent protein kinase from the nucleus to the
cytosol, suggesting one potential mechanism whereby C225 may influence
the cellular response to radiation. Immunohistochemical analysis of SCC
tumor xenografts after systemic administration of C225 demonstrated
inhibition of the in vivo expression of tumor
angiogenesis markers, including vascular endothelial growth factor and
Factor VIII. Taken together, the collective data suggest that the
profound in vivo antitumor activity identified in the
xenograft setting when C225 is combined with radiation derives from
more than simply the antiproliferative and cell cycle effects of EGFR
system inhibition. In addition to antiproliferative growth inhibition,
EGFR blockade with C225 appears to influence the capacity of human SCCs
to effect DNA repair after exposure to radiation, and to express
classic markers of tumor angiogenesis.
573 citations
••
TL;DR: It is shown that CD133 negative glioma cells are tumorgenic in nude rats, and thatCD133 positive cells can be obtained from these tumors, suggesting that it may be involved during brain tumor progression.
Abstract: CD133 is a cell surface marker expressed on progenitors of haematopoietic and endothelial cell lineages. Moreover, several studies have identified CD133 as a marker of brain tumor-initiating cells. In this study, human glioblastoma multiforme biopsies were engrafted intracerebrally into nude rats. The resulting tumors were serially passaged in vivo, and monitored by magnetic resonance imaging. CD133 expression was analyzed at various passages. Tumors initiated directly from the biopsies expressed little or no CD133, and showed no contrast enhancement suggesting an intact blood-brain barrier. During passaging, the tumors gradually displayed more contrast enhancement, increased angiogenesis and a shorter survival. Real-time qPCR and immunoblots showed that this was accompanied by increased CD133 expression. Primary biopsy spheroids and xenograft tumors were subsequently dissociated and flow sorted into CD133 negative and CD133 positive cell populations. Both populations incorporated BrdU in cell culture, and expressed the neural precursor marker nestin. Notably, CD133 negative cells derived from 6 different patients were tumorgenic when implanted into the rat brains. For 3 of these patients, analysis showed that the resulting tumors contained CD133 positive cells. In conclusion, we show that CD133 negative glioma cells are tumorgenic in nude rats, and that CD133 positive cells can be obtained from these tumors. Upon passaging of the tumors in vivo, CD133 expression is upregulated, coinciding with the onset of angiogenesis and a shorter survival. Thus, our findings do not suggest that CD133 expression is required for brain tumor initiation, but that it may be involved during brain tumor progression.
573 citations
••
TL;DR: It is shown that colorectal cancer (CRC) derived exosomal miR-25-3p promotes vascular leakiness and angiogenesis, CRC metastasis, and is upregulated in CRC pateints with metastasis.
Abstract: Cancer-derived exosomes are considered a major driver of cancer-induced pre-metastatic niche formation at foreign sites, but the mechanisms remain unclear. Here, we show that miR-25-3p, a metastasis-promoting miRNA of colorectal cancer (CRC), can be transferred from CRC cells to endothelial cells via exosomes. Exosomal miR-25-3p regulates the expression of VEGFR2, ZO-1, occludin and Claudin5 in endothelial cells by targeting KLF2 and KLF4, consequently promotes vascular permeability and angiogenesis. In addition, exosomal miR-25-3p from CRC cells dramatically induces vascular leakiness and enhances CRC metastasis in liver and lung of mice. Moreover, the expression level of miR-25-3p from circulating exosomes is significantly higher in CRC patients with metastasis than those without metastasis. Our work suggests that exosomal miR-25-3p is involved in pre-metastatic niche formation and may be used as a blood-based biomarker for CRC metastasis. The mechanisms underlying pre-metastatic niche formation by cancer derived exosomes is unclear. Here they show that colorectal cancer (CRC) derived exosomal miR-25-3p promotes vascular leakiness and angiogenesis, CRC metastasis, and is upregulated in CRC pateints with metastasis, and suggest miR-25-3p as a biomarker for CRC metastasis.
573 citations
••
TL;DR: TEM cells may account for the proangiogenic activity of bone marrow–derived cells in tumors, may represent a new target for drug development and may provide the means for selective gene delivery and targeted inhibition of tumor angiogenesis.
Abstract: Angiogenic tumor vessels are promising targets for the activity and the selective delivery of cancer therapeutics. The bone marrow contributes different cell types to the tumor stroma, including hematopoietic cells and, as recently suggested, vascular endothelial cells (ECs). Thus, transplantation of genetically modified bone marrow progenitors may represent a vehicle for the transport of gene therapy to tumors. We transduced bone marrow progenitors with lentiviral vectors expressing genes from transcription-regulatory elements of Tie2/Tek gene. When tumors were grown in the transplanted mice, the new vector marked a distinct hematopoietic population that 'homed' to the tumor and closely interacted with vascular ECs at the tumor periphery. These Tie2-expressing mononuclear (TEM) cells had a distinguishable phenotype and were present selectively at angiogenic sites. Unexpectedly, we did not find bone marrow-derived ECs in tumor vessels when we transplanted bone marrow progenitors constitutively expressing a marker gene from the Tie2 or ubiquitously active promoters. By delivering a 'suicide' gene, we selectively eliminated the TEM cells and achieved substantial inhibition of angiogenesis and slower tumor growth without systemic toxicity. Thus, TEM cells may account for the proangiogenic activity of bone marrow-derived cells in tumors, may represent a new target for drug development and may provide the means for selective gene delivery and targeted inhibition of tumor angiogenesis.
572 citations